Marked differences in CCR5 expression and activation levels in two South African populations

Immunology

Volumn 136, Issue 4, 2012, Pages 397-407

  Picton, Anabela C P ^a,b   Shalekoff, Sharon ^a   Paximadis, Maria ^a   Tiemessen, Caroline T ^a,b  

^a NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

CCR5; HLA DR; South African populations

Indexed keywords

CD16 ANTIGEN; CD56 ANTIGEN; CHEMOKINE RECEPTOR CCR5;

ADULT; ANTIGEN EXPRESSION; ARTICLE; BLOOD CELL; CAUCASIAN; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; COHORT ANALYSIS; DISEASE COURSE; DISEASE PREDISPOSITION; ETHNIC DIFFERENCE; ETHNIC GROUP; FEMALE; FLOW CYTOMETRY; HIGH RISK POPULATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; NATURAL KILLER CELL; NEGRO; POPULATION RESEARCH; PRIORITY JOURNAL; SOUTH AFRICA; T LYMPHOCYTE SUBPOPULATION;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; AGING; ANTIGENS, CD56; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DISEASE PROGRESSION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; RECEPTORS, CCR5; RECEPTORS, IGG; SOUTH AFRICA; YOUNG ADULT;

EID: 84863191371     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2012.03592.x     Document Type: Article

References (56)

1. Lee B, Sharron M, Montaner LJ, Weissman D, Doms RW. Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc Natl Acad Sci U S A 1999; 96:5215-20.
2. Liu R, Paxton WA, Choe S et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86:367-77.
3. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 1998; 72:2855-64.
4. Heredia A, Gilliam B, DeVico A et al. CCR5 density levels on primary CD4 T cells impact the replication and Enfuvirtide susceptibility of R5 HIV-1. AIDS 2007; 21:1317-22.
5. Lin YL, Mettling C, Portales P, Reynes J, Clot J, Corbeau P. Cell surface CCR5 density determines the postentry efficiency of R5 HIV-1 infection. Proc Natl Acad Sci U S A 2002; 99:15590-5.
6. + T cell surface CCR5 density as a determining factor of virus load in persons infected with human immunodeficiency virus type 1. J Infect Dis 2000; 181:927-32.
7. + T cell surface CC chemokine receptor 5 density in human immunodeficiency virus type 1 vertical infection. J Infect Dis 2002; 185:1055-61.
8. Reynes J, Portales P, Segondy M et al. CD4 T cell surface CCR5 density as a host factor in HIV-1 disease progression. AIDS 2001; 15:1627-34.
9. Heredia A, Latinovic O, Gallo RC, Melikyan G, Reitz M, Le N, Redfield RR. Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1. Proc Natl Acad Sci U S A 2008; 105:20476-81.
10. Ketas TJ, Kuhmann SE, Palmer A, Zurita J, He W, Ahuja SK, Klasse PJ, Moore JP. Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands. Virology 2007; 364:281-90.
11. Desmetz C, Lin YL, Mettling C, Portales P, Rabesandratana H, Clot J, Corbeau P. The strength of the chemotactic response to a CCR5 binding chemokine is determined by the level of cell surface CCR5 density. Immunology 2006; 119:551-61.
12. Dean M, Carrington M, Winkler C et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996; 273:1856-62.
13. Samson M, Libert F, Doranz BJ et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382:722-5.
14. Wu L, Paxton WA, Kassam N et al. CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J Exp Med 1997; 185:1681-91.
15. Galvani AP, Novembre J. The evolutionary history of the CCR5-Delta32 HIV-resistance mutation. Microbes Infect 2005; 7:302-9.
16. Petersen DC, Kotze MJ, Zeier MD, Grimwood A, Pretorius D, Vardas E, van Rensburg EJ, Hayes VM. Novel mutations identified using a comprehensive CCR5-denaturing gradient gel electrophoresis assay. AIDS 2001; 15:171-7.
17. Moore JP, Trkola A, Dragic T. Co-receptors for HIV-1 entry. Curr Opin Immunol 1997; 9:551-62.
18. Gonzalez E, Kulkarni H, Bolivar H et al. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 2005; 307:1434-40.
19. Lin YL, Mettling C, Portales P, Rouzier R, Clot J, Reynes J, Corbeau P. The chemokine CCL5 regulates the in vivo cell surface expression of its receptor, CCR5. AIDS 2008; 22:430-2.
20. + T cells. J Clin Immunol 2001; 21:402-9.
21. + T cells. J Clin Immunol 2001; 21:116-25.
22. + T lymphocytes in HIV-infected patients treated with interleukin-2. ANRS 048 IL-2 Study Group. AIDS 1999; 13:455-63.
23. + lymphocytes in vivo. J Infect Dis 2000; 181:933-8.
24. + T lymphocytes have elevated CCR5 expression and produce the majority of R5-tropic HIV-1 RNA in vivo. J Virol 2011; 85:10189-200.
25. Moriuchi H, Moriuchi M, Fauci AS. Cloning and analysis of the promoter region of CCR5, a coreceptor for HIV-1 entry. J Immunol 1997; 159:5441-9.
26. Ostrowski MA, Justement SJ, Catanzaro A et al. Expression of chemokine receptors CXCR4 and CCR5 in HIV-1-infected and uninfected individuals. J Immunol 1998; 161:3195-201.
27. Shalekoff S, Pendle S, Johnson D, Martin DJ, Tiemessen CT. Distribution of the human immunodeficiency virus coreceptors CXCR4 and CCR5 on leukocytes of persons with human immunodeficiency virus type 1 infection and pulmonary tuberculosis: implications for pathogenesis. J Clin Immunol 2001; 21:390-401.
28. Picton AC, Paximadis M, Tiemessen CT. Genetic variation within the gene encoding the HIV-1 CCR5 coreceptor in two South African populations. Infect Genet Evol 2010; 10:487-94.
29. Berhanu D, Mortari F, De Rosa SC, Roederer M. Optimized lymphocyte isolation methods for analysis of chemokine receptor expression. J Immunol Methods 2003; 279:199-207.
30. Naranbhai V, Bartman P, Ndlovu D, Ramkalawon P, Ndung'u T, Wilson D, Altfeld M, Carr WH. Impact of blood processing variations on natural killer cell frequency, activation, chemokine receptor expression and function. J Immunol Methods 2011; 366:28-35.
31. Shalekoff S, Tiemessen CT. Duration of sample storage dramatically alters expression of the human immunodeficiency virus coreceptors CXCR4 and CCR5. Clin Diagn Lab Immunol 2001; 8:432-6.
32. Giltay EJ, Fonk JC, von Blomberg BM, Drexhage HA, Schalkwijk C, Gooren LJ. In vivo effects of sex steroids on lymphocyte responsiveness and immunoglobulin levels in humans. J Clin Endocrinol Metab 2000; 85:1648-57.
33. Mo R, Chen J, Grolleau-Julius A, Murphy HS, Richardson BC, Yung RL. Estrogen regulates CCR gene expression and function in T lymphocytes. J Immunol 2005; 174:6023-9.
34. + T cells is stable during a 2-year longitudinal study but varies widely between individuals. J Neurovirol 2003; 9:291-9.
35. Mo R, Chen J, Han Y, Bueno-Cannizares C, Misek DE, Lescure PA, Hanash S, Yung RL. T cell chemokine receptor expression in aging. J Immunol 2003; 170:895-904.
36. Yung RL, Mo R. Aging is associated with increased human T cell CC chemokine receptor gene expression. J Interferon Cytokine Res 2003; 23:575-82.
37. Kalinkovich A, Borkow G, Weisman Z, Tsimanis A, Stein M, Bentwich Z. Increased CCR5 and CXCR4 expression in Ethiopians living in Israel: environmental and constitutive factors. Clin Immunol 2001; 100:107-17.
38. Funke J, Durr R, Dietrich U, Koch J. Natural killer cells in HIV-1 infection: a double-edged sword. AIDS Rev 2011; 13:67-76.
39. Valentin A, Rosati M, Patenaude DJ et al. Persistent HIV-1 infection of natural killer cells in patients receiving highly active antiretroviral therapy. Proc Natl Acad Sci U S A 2002; 99:7015-20.
40. + NK cells can be productively infected with HIV, leading to downregulation of CD4 expression and changes in function. Virology 2009; 387:59-66.
41. Harada H, Goto Y, Ohno T, Suzu S, Okada S. Proliferative activation up-regulates expression of CD4 and HIV-1 co-receptors on NK cells and induces their infection with HIV-1. Eur J Immunol 2007; 37:2148-55.
42. Clerici M, Butto S, Lukwiya M et al. Immune activation in africa is environmentally-driven and is associated with upregulation of CCR5. Italian-Ugandan AIDS Project. AIDS 2000; 14:2083-92.
43. Cohen CR, Moscicki AB, Scott ME et al. Increased levels of immune activation in the genital tract of healthy young women from sub-Saharan Africa. AIDS 2010; 24:2069-74.
44. Begaud E, Chartier L, Marechal V et al. Reduced CD4 T cell activation and in vitro susceptibility to HIV-1 infection in exposed uninfected Central Africans. Retrovirology 2006; 3:35.
45. + T cell activation is associated with low susceptibility to HIV-1 infection. J Immunol 2005; 175:6117-22.
46. Chaplin DD. Overview of the immune response. J Allergy Clin Immunol 2010; 125(2 Suppl 2):S3-23.
47. Evans RL, Faldetta TJ, Humphreys RE, Pratt DM, Yunis EJ, Schlossman SF. Peripheral human T cells sensitized in mixed leukocyte culture synthesize and express Ia-like antigens. J Exp Med 1978; 148:1440-5.
48. Ko HS, Fu SM, Winchester RJ, Yu DT, Kunkel HG. Ia determinants on stimulated human T lymphocytes. Occurrence on mitogen- and antigen-activated T cells. J Exp Med 1979; 150:246-55.
49. Evans JH, Horowitz A, Mehrabi M, Wise EL, Pease JE, Riley EM, Davis DM. A distinct subset of human NK cells expressing HLA-DR expand in response to IL-2 and can aid immune responses to BCG. Eur J Immunol 2011; 41:1924-33.
50. Roncarolo MG, Bigler M, Haanen JB, Yssel H, Bacchetta R, de Vries JE, Spits H. Natural killer cell clones can efficiently process and present protein antigens. J Immunol 1991; 147:781-7.
51. Hanna J, Gonen-Gross T, Fitchett J et al. Novel APC-like properties of human NK cells directly regulate T cell activation. J Clin Invest 2004; 114:1612-23.
52. de Roda Husman AM, Blaak H, Brouwer M, Schuitemaker H. CC chemokine receptor 5 cell-surface expression in relation to CC chemokine receptor 5 genotype and the clinical course of HIV-1 infection. J Immunol 1999; 163:4597-603.
53. Shalekoff S, Tiemessen CT. CCR5 delta32 heterozygosity is associated with an increase in CXCR4 cell surface expression. AIDS Res Hum Retroviruses 2003; 19:531-3.
54. Camargo JF, Quinones MP, Mummidi S et al. CCR5 expression levels influence NFAT translocation, IL-2 production, and subsequent signaling events during T lymphocyte activation. J Immunol 2009; 182:171-82.
55. Dolan MJ, Kulkarni H, Camargo JF et al. CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms. Nat Immunol 2007; 8:1324-36.
56. Levy JA. HIV pathogenesis: knowledge gained after two decades of research. Adv Dent Res 2006; 19:10-6.